Mecasermin
| Evidence Level: L5 | Predicted Indications: 4 |
Table of Contents
Mecasermin: Monosomy X
One-Sentence Summary
Mecasermin is a recombinant form of insulin-like growth factor 1 (IGF-1), originally used for growth hormone insensitivity syndrome (including Laron syndrome). The TxGNN model predicts it may be effective for monosomy X (Turner syndrome), but no clinical trials and no publications were identified to support this prediction, so it is a computational signal only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Monosomy X |
| TxGNN Prediction Score | 0.9959 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, mecasermin is an IGF-1 replacement, its use in growth hormone insensitivity (severe primary IGF-1 deficiency) is established, and mechanistically it may be relevant to other conditions of impaired growth.
Monosomy X (Turner syndrome) is characterised by short stature, and the growth axis is connected to IGF-1 biology. However, Turner syndrome is typically not a state of GH/IGF-1 insensitivity, and it is usually managed with growth hormone. The high score (0.9959) is therefore a computational prediction only, and the mechanistic link is weak.
Other conditions in the top 10 predictions have little or no biological rationale:
- Predictions such as Wolman disease and esophageal varices (bleeding and non-bleeding, which appear to be duplicate entries) show no identified mechanistic link. Their scores come from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13116H | Increlex | Solution for injection 40 mg in 4 mL (10 mg per mL) | Not available in the data compiled for this report |
Safety Considerations
Drug Interactions: 24 interactions were recorded, all rated Moderate. They involve glucose-lowering agents, which is consistent with the hypoglycaemia risk of mecasermin:
- Sulfonylureas: chlorpropamide, acetohexamide, glimepiride, glipizide, glyburide
- Meglitinide: nateglinide
- Insulins: human (regular, isophane, zinc, zinc extended, inhaled rapid-acting), aspart (including protamine), degludec, detemir, glargine, glulisine, lispro (including protamine)
Only 20 of the 24 interactions were listed in the data compiled for this report.
Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a model score, with no clinical trials or literature. The mechanistic link is weak, because Turner syndrome is not usually a GH/IGF-1 insensitivity state and is already managed with growth hormone. The safety profile (hypoglycaemia, intracranial hypertension, tissue proliferation) also calls for evidence before any new use.
To proceed, the following is needed:
- Mechanism of action data for mecasermin
- The TGA Product Information, including approved indication, warnings and contraindications
- A systematic literature and trial registry search (including ANZCTR) for mecasermin in Turner syndrome
- Manual review of the STAT5B-related GH insensitivity subtype to check whether it already falls within the approved indication
- Clinical input on whether IGF-1 therapy has any role alongside standard growth hormone treatment in Turner syndrome
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.